Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 100 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,316,661 | +49.7% | 241,589 | +86.6% | 0.00% | – |
Q2 2023 | $879,292 | +60.4% | 129,498 | +18.3% | 0.00% | – |
Q1 2023 | $548,255 | +92510.6% | 109,432 | -9.7% | 0.00% | – |
Q4 2022 | $592 | -100.0% | 121,136 | -8.7% | 0.00% | -100.0% |
Q3 2022 | $1,911,000 | -42.6% | 132,611 | -39.7% | 0.00% | 0.0% |
Q2 2022 | $3,329,000 | +52.8% | 219,967 | +20.0% | 0.00% | 0.0% |
Q1 2022 | $2,178,000 | -29.9% | 183,368 | -4.4% | 0.00% | 0.0% |
Q4 2021 | $3,109,000 | -13.2% | 191,802 | +52.8% | 0.00% | 0.0% |
Q3 2021 | $3,582,000 | – | 125,522 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |